EUVIMEDEUVIMED entdecken
Fallbericht

Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis

Matthew Fenech iD, Ayodeji Ajanaku, James Hsuan iD, Austin McCormick, Simon Shamas, Nima Ghadiri iD

Orbit · 04.05.2025 · 44 (3) · 335-339

DOI: 10.1080/01676830.2024.2385010 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Orbit, online erschienen am 07.08.2024. Verfasst von Matthew Fenech und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Dacryocystitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoints refer to mechanisms entrusted with the modulation of immune responses in peripheral tissues and are required for minimising collateral damage. Immune checkpoint inhibitors (ICPi) work through numerous pathways, including the anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti-PD-1 (programmed cell death protein 1) and the PD-L1 (protein cell death protein-ligand-1) pathways. They are proving to be an exciting therapeutic avenue in the attempt to activate anti-tumour activity. Ipilimumab is a fully human monoclonal antibody working on the anti-CTLA-4 pathway, while nivolumab and pembrolizumab are humanised monoclonal IgG4 antibodies that work on the PD-1 pathway. Despite a growing body of research pertinent to these novel therapies, early indications show that they are limited by their side effect profile. Furthermore, their efficacy appears to be greater in cancers with a high mutational burden. We present two female patients with bilateral reactive dacryoadenitis secondary to ICPi therapy, a finding that to the best of our knowledge was not previously described in the literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsDacryocystitisHumansFemaleNivolumabAntibodies, Monoclonal, HumanizedIpilimumabMiddle AgedAgedTomography, X-Ray Computed

Stichwörter der Autor:innen

Immune checkpoint inhibitorsIrAEsipilimumablacrimal gland biopsynivolumabpembrolizumabreactive dacryoadenitis

Substanzen

Immune Checkpoint InhibitorspembrolizumabNivolumabAntibodies, Monoclonal, HumanizedIpilimumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Department of Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK.

ORCID-Profile: Matthew Fenech, James Hsuan, Nima Ghadiri

Zitieren

APA

Fenech, M., Ajanaku, A., Hsuan, J., McCormick, A., Shamas, S., & Ghadiri, N. (2025). Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis. Orbit, 44(3), 335-339. https://doi.org/10.1080/01676830.2024.2385010

Vancouver

Fenech M, Ajanaku A, Hsuan J, McCormick A, Shamas S, Ghadiri N. Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis. Orbit. 2025;44(3):335-339. doi:10.1080/01676830.2024.2385010

BibTeX
@article{Fenech2025,
  author = {Fenech, Matthew and Ajanaku, Ayodeji and Hsuan, James and McCormick, Austin and Shamas, Simon and Ghadiri, Nima},
  title = {Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis},
  journal = {Orbit},
  year = {2025},
  volume = {44},
  number = {3},
  pages = {335--339},
  doi = {10.1080/01676830.2024.2385010}
}
Kostenlos starten →